2007 Bush vetoed the bill. “It is estimated that if this program were to become law, one out of every three persons that would subscribe to the new expanded SCHIP would leave private insurance,” the president reasoned. “The
As of 2005, 10 million people in the U.S. take thyroxine. When one considered that Abbott’s Synthroid is the most popular form of thyroxine, and the second-most prescribed drug in the U.S., one starts to understand the financial rivalry between Synthroid and natural thyroid competitors. L...